Our study provided mechanistic insights and preclinical rationale for modulating the STAT1 regulon as a neoadjuvant regimen for MCT-primed breast tumors to achieve the maximum clinical benefit of the anti-PD1 immunotherapy. This evidence concerns the gene STAT1 and breast neoplasm.